Moderna stock jumps 6%, extending a 137% rally on promising cancer vaccine data.
Moderna's stock surged 6% to $154, extending a 137% gain over the past month driven by promising Phase 2b melanoma vaccine data presented at ASCO 2026. The data showed a 49% reduction in risk of recurrence or death when combining Moderna's intismeran...
